Objective:To investigate the expression of DHX37,PD-L1,CD4+and CD8+and the clinicopathological features in lymphoepithelioma-like gastric carcinoma(LELGC).Methods:10 cases of LELGC were collected and immunohistochemistry were used to analyze DHX37,PD-L1,CD4+,CD8+,and mismatch repair gene proteins(MLH1,MSH2,MSH6 and PMS2),in situ hybridization was performed to detect Epstein-Barr virus-encoded RNA(EBER)and investigate their clinicopathological characteristics.Selected 10 cases of conventional gastric adenocarcinoma with similar clinical features for comparison.Results:In a sample of 10 cases of LELGC,the average age was approximately(55.00±10.19)years,there were 8 male and 2 female patients.6 cases occurred in the body of the stomach,2 in the gastric angle,1 in the cardia,and 1 in the antrum,which was also a residual gastric cancer.All 10 surgically resected specimens presented with ulcerative lesions,with the smallest diameter measuring 1.7 cm and the largest 7.0 cm.All 10 LELGC cases showed intact mismatch repair protein function(Mismatch Repair Proficient,pMMR)and were EBER-positive,with the number of CD8+-positive T cells exceeding that of CD4+-positive T cells in each case.The average CPS for PD-L1 was(35.00±14.53),the av-erage positive expression count for DHX37 was(42.26±13.11).In LELGC,the proportion of DHX37 expression in lymphocytes was lower than that in conventional gastric adenocarcinoma(P＜0.05),and this condition also exhibited higher PD-L1 expression levels(P＜0.05).Conclusion:The diagnosis and prognosis assessment of LELGC rely on characteristic pathological morphology and molecu-lar testing.The stroma is predominantly infiltrated by CD8+-positive T cells.Compared to conventional gastric adenocarcinoma,LELGC exhibits higher PD-L1 and lower DHX37 expression.These features may be associated with better prognosis and higher sensitivity to im-munotherapy in these patients,suggesting that different expression patterns of DHX37,CD4+,CD8+,and PD-L1 might have significant implications for the prognosis of LELGC or conventional gastric adenocarcinoma.